Physician profile
John G Lieb
NPI 1467523365
$5,284.11
in general payments reported to CMS, 2019-2025
10 companies · $749 in 2025
The $749 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $139 · 2021: $1,650 · 2022: $2,100 · 2023: $48.12 · 2024: $59.29 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $700 · Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $700.00 |
| Food and Beverage | $155.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $3,750.00 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $700.00 | 2025 | Zenpep |
| Allergan, INC. | $165.03 | 2019 | |
| Vivus LLC | $124.53 | 2019 | |
| Alcresta Therapeutics, INC. | $121.05 | 2019 | |
| Boston Scientific Corporation | $108.87 | 2019 | |
| Mauna Kea Technologies, INC. | $96.63 | 2023-2025 | |
| Abbvie INC. | $91.30 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.41 | 2019-2020 | |
| Janssen Biotech, INC. | $59.29 | 2024 | Tremfya, Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.